PHARMACEUTICAL COMPOSITION FOR PREVENTING, TREATING AND CURING ROSACEA, COMPRISING SNAIL SLIME, CHAMOMILE AND PROPOLIS

Abstract

The invention relates to a pharmaceutical composition consisting of snail slime Helix aspersa muller (Cryptomphalus aspersus) (20% to 50%), camomile extract (1-4%), propolis 1l-4%), and pharmaceutically acceptable excipients and/or additives for forming a formulation of low, intermediate or high viscosity (10 to 1000 Pa-s). Said composition is in the form of a lotion, soap, cream or gel, which is embedded in a gauze-type fabric in the form of a plaster that can be applied to lesions caused by the different types of rosacea. The composition can also contain natural extracts such as marigold extract, honey and vegetable oils. The invention also relates to the method for producing the composition and to the use thereof for preparing a medicament or device for preventing, treating or curing lesions caused by rosacea, on the skin of the face or the body.

Claims

1-12. (canceled)

13. A pharmaceutical composition for treating rosacea lesions comprising: about up to 20% snail slime from Helix aspersa Muller (Cryptophalus asperses); about up to 8% chamomile extract; and about up to 4% propolis; wherein said snail slime, chamomile extract and propolis are dissolved in a base including one or more excipients, and said composition has a viscosity between 10-1000 Pa-s.

14. The composition of claim 13, wherein said viscosity is limited to 500 Pa S.

15. the composition of claim 13, wherein said chamomile extract is limited to 5%.

16. The composition of claim 13, wherein said composition is embedded into a patch or bandage.

17. The composition of claim 13, wherein said composition is in the form of a lotion.

18. The composition of claim 13, wherein said composition is in the form of a soap.

19. The composition of claim 13, wherein said composition is in the form of a cream or gel.

20. The composition of claim 13, wherein said composition further comprising at least one of nettle extract, calendula extract, and propolis.

21. A method of manufacture of a gel patch for treatment of rosacea comprising the steps of: sterilizing an amount of body cream by autoclaving at a temperature above 100 C; adding and stirring in an amount of sterilized snail slime; adding an effective amount of petroleum jelly and distilled water and homogenizing the combined solution thereby formulating a gelatinous formulation; and soaking a patch in said formulation; wherein the ratio of the quantity of body cream to snail slime is about 5:3 by weight and the viscosity of the formulation is between 50 and 1,000 pa s.

22. The method of claim 21, wherein said viscosity is limited to 500 pa s.

23. The method of claim 21, wherein said snail slime is limited to 20% by weight of said formulation.

24. The method of claim 21, wherein said snail slime is limited to 5% by weight of said formulation.

25. The method of claim 21, wherein said composition further comprises chamomile extract.

26. The method of claim 21, wherein said composition further comprises propolis.

27. A method of treating rosacea in a patient comprising the steps of: sterilizing a measure of body cream by autoclaving at a temperature above 100 C; adding and stirring in a measure of sterilized snail slime; adding an effective amount of petroleum jelly and distilled water and homogenizing the combined solution thereby formulating a gelatinous formulation; and soaking an absorbent element in said formulation and applying said absorbent element to a patient at the site of a lesion; wherein the ratio of body cream to snail slime is about 5:3 and the viscosity of the formulation is between 500 and 1,000 pa s.

28. The method of claim 27, wherein said absorbent element is applied using a patch overnight and the step of applying a similarly soaked patch is repeated for 7 to 10 days.

29. The method of claim 27, wherein said absorbent element is a sponge and said sponge is applied to a lesion, followed by application of a body cream until absorption.

30. The method of claim 27, wherein said rosacea is a erythematous-telangietic type.

31. The method of claim 27, wherein said rosacea is a tyrosine type.

32. The method of claim 27, wherein said rosacea is a phylogenetic type.

Description

BRIEF DESCRIPTION OF THE FIGURES

[0066] FIG. 1: Photograph of Helix aspersa Müller snail strain

[0067] FIG. 2: Example of characteristic lesions of rosacea. a) Erythematous-telangiectic rosacea, b) Papulo-pustular rosacea, c) Rosacea-Fimatosa.

[0068] FIG. 3: Shape and dimensions of the various gauze patches or gel-embedded bandages of the invention for therapeutic purposes.

REFERENCES

[0069] Abad R, Therapeutic and cosmetic compositions for treatment of skin, U.S. Pat. No. 5,538,740, 1996. [0070] Chang B P, Kurian A, Barankin B. Rosacea: an update on medical therapies. Skin Therapy Lett. 2014 June; 19(3):1-4.). [0071] Cribier B. Physiopathology of rosácea. Ann Dermatol Venereol. 2014 September; 141 Suppl 2:S158-64. [0072] Del Rosso J Q, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L F, Stein-Gold L, Berson D, Zaenglein. A Consensus recommendations from the American Acne &; Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014 March; 93(3):134-8. [0073] Denda S, Denda M, Inoue K, Hibino T. Glycolic acid induces keratinocyte proliferation in a skin equivalent model via TRPV1 activation. J DermatolSci. 2010 February; 57(2):108-13. [0074] Elson M L. The molecular structure of glycolic acid and its importance in dermatology. Cosmetic Dermatology; 6(7): 35-40, 1993. [0075] Huynh T T. Burden of Disease: The Psychosocial Impact of Rosacea on a Patient's Quality of Life. Am Health Drug Benefits 2013, 6(6): 348-354. [0076] Moustafa F A, Sandoval L F, Feldman S R. Rosacea: new and emerging treatments. Drugs. 2014 September; 74(13):1457-65. [0077] Sage E H & Gray W R 1977 Evolution of elastin and elastin structure, p 291. in; Advances in Experimental Medicine and Biology, vol. 79 L B Sandberg & C Franzblaw, eds) Plenum Press, NY & London). [0078] Sarnoff D S. Therapeutic update on Rosacea. J Drugs Dermatol. 2014 January; 13(1):10-1. Review. [0079] Schmutz J L. Signs and symptoms of rosácea. Ann Dermatol Venereol. 2014 September; 141 Suppl 2:S151-7. [0080] Sznitowska M, Janicki S., The effect of vehicle on allantoin penetration into human skin from an ointment for improving scar elasticity. Pharmazie. 1988 March; 43(3): 218. [0081] Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013 December; 69(6 Suppl 1):S27-35. [0082] Tribó M J, Parrado C, Rais B et al. Preliminary results of the efficacy of intensive treatment with Cryptomphalus aspersa (SCA) secretion in cutaneous photo-aging therapy. Med Cutanlber Lat Am. 2004;32:265-270. [0083] Tüzün Y, Wolf R, Kutlubay Z, Karaku O, Engin B. Rosacea and rhinophyma. Clin Dermatol. 2014 January-February; 32(1):35-46. [0084] Young G L, Jewell D. (2002). Creams for preventing stretch marks in pregnancy. Cochrane Database Syst Rev., (2): CD000066.